CD38 and chronic lymphocytic leukemia: a decade later

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

T cell-mediated immunity Chapter 8
B – CELL ACTIVATION Where and how do all these things take place?
T-cell & B cell receptors – role in immune response & Major Histocompatibility Complex (MHC) Lecture 6 4/10/2015.
Cell Communication Chapter 9.
Cell Communication Chapter 9.
Chapter 12 B-Cell Activation and Differentiation Dr. Capers
You Must Know  3 stages of cell communication Reception, transduction, & response  How G-protein-coupled receptors receive cell signals & start transduction.
Cell Communication Chapter 9. 2 Cell Communication Communication between cells requires: ligand: the signaling molecule receptor protein: the molecule.
B Cell Activation and Antibody Production Chapter 12.
1 3/12/2016 Acquired Immunity Hugh B. Fackrell filename : Kuby 01B7.
T-cell & B-cell receptors – Role in the Immune Response
Cell Communication Chapter 9. Cell Communication Communication between cells requires: ligand: the signaling molecule receptor protein: the molecule to.
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
Activation of T Lymphocytes
Immune Receptors and Signal Transduction
Thymocyte development summary
Potassium Channels and Proliferation of Vascular Smooth Muscle Cells
CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation.
and CHAPTER 6 Major Histocompatibility Complex (MHC) Molecules
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes by Rajendra N. Damle, Fabio.
EBV DNA: a Hodgkin lymphoma biomarker?
Cell Communication Chapter 9.
Fledgling prognostic markers in CLL
Another Notch on the belt
CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood by Mohamed F. Elshal,
Essentials of Th17 cell commitment and plasticity
Hugh B. Fackrell filename : Kuby 01B7
SOX11 holds mantle cell lymphoma’s key to home
Lymphoma dissemination: the other face of lymphocyte homing
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Cell Communication Chapter 6.
by Craig Murdoch, Athina Giannoudis, and Claire E. Lewis
Targeting kinases in CML CLL
Cell Communication.
by Nicholas Chiorazzi, and Manlio Ferrarini
Figure 2 Schematic representation illustrating the journey
دکتر مجیری داروساز متخصص فارماکولوژی
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Figure 1 Activation and signalling of IL-1
Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukemia cells by Simon T. Abrams, Benjamin R. B. Brown,
Pathogenic Roles of B Cells in Human Autoimmunity
Chemokines and chemokine receptors: here, there, and everywhere
Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD by Joanne E. Croudace, Charlotte F.
Hepatitis C and Lymphoproliferative Disorders: From Mixed Cryoglobulinemia to Non- Hodgkin's Lymphoma  Lenna A. Martyak, Melina Yeganeh, Sammy Saab  Clinical.
Volume 75, Issue 11, Pages (June 2009)
Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA)‏
Andrey S. Shaw, Michael L. Dustin  Immunity 
Nat. Rev. Nephrol. doi: /nrneph
Naomi E. Harwood, Facundo D. Batista  Immunity 
Fritz Melchers, Antonius G Rolink, Christoph Schaniel  Cell 
Multistep Pathogenesis of Autoimmune Disease
Volume 84, Issue 3, Pages (February 1996)
Volume 76, Issue 5, Pages (September 2009)
Drug-Receptor Interactions
Chemokines: Key Players in Innate and Adaptive Immunity
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
HUS and atypical HUS by T. Sakari Jokiranta Blood
Lymphatic vessels, inflammation, and immunity.
Follicular Helper T Cells: Lineage and Location
Myeloproliferative neoplasms and thrombosis
Consequences of complement activation.
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Wolfgang Warsch, Christoph Walz, and Veronika Sexl
The interplay of leukemia cells and the bone marrow microenvironment
Airway smooth muscle: An immunomodulatory cell
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
A schematic diagram showing the mechanism by which L5 triggers platelet activation and aggregation. A schematic diagram showing the mechanism by which.
Presentation transcript:

CD38 and chronic lymphocytic leukemia: a decade later by Fabio Malavasi, Silvia Deaglio, Rajendra Damle, Giovanna Cutrona, Manlio Ferrarini, and Nicholas Chiorazzi Blood Volume 118(13):3470-3478 September 29, 2011 ©2011 by American Society of Hematology

Structural and functional characteristics of the human CD38 molecule. Structural and functional characteristics of the human CD38 molecule. In human B cells, CD38 is expressed as an integral surface membrane molecule, often in a dimeric conformation. As an enzyme, CD38 may interact with the substrate ligands NAD+ and NADP+, which are converted to cADPR, ADPR, and NAADP, all intracellular Ca2+-mobilizing agents. CD38 also interacts with non-substrate ligands, including CD31 and hyaluronic acid, which regulate cell-cell and cell-matrix contacts. On the plasma membrane, CD38 displays preferential localization in membrane lipid microdomains in close contact with the BCR complex (CD19/CD81) and with molecules regulating homing (CXCR4 and CD49d). CD38 engagement by means of the natural ligand CD31 (or surrogate agonistic mAb) triggers the activation of an intracellular signaling pathway, which includes ZAP-70 and ERK1/2 as major players. These signals increase chemotaxis as well as proliferation of neoplastic B cells. The interplay between the enzymatic and receptor activities still needs to be determined in the CLL context. Fabio Malavasi et al. Blood 2011;118:3470-3478 ©2011 by American Society of Hematology

Proposed model explaining a role of CD38 in the pathogenesis and progression of CLL. (A) CD38+ CLL cells (red) are more sensitive to CXCL12 signals, with a higher propensity to home to lymphoid tissues than the CD38− counterpart (brown). Proposed model explaining a role of CD38 in the pathogenesis and progression of CLL. (A) CD38+ CLL cells (red) are more sensitive to CXCL12 signals, with a higher propensity to home to lymphoid tissues than the CD38− counterpart (brown). (B) Once inside the LN PCs, CLL lymphocytes come into contact with accessory cells, such as nurse-like (NLC), follicular dendritic (FDC), stromal, endothelial, mesenchymal, and T cells. The presence of antigen and accessory signals leads to proliferation and potentially to acquisition of novel genetic lesions, which promote clonal evolution and disease progression. These events are more apparent in the CD38+ subsets. The C > G SNP occurring in a region of CD38 critical for transcriptional regulation adds an additional element of complexity, potentially affecting the levels of CD38 expression after microenvironmental interactions. Fabio Malavasi et al. Blood 2011;118:3470-3478 ©2011 by American Society of Hematology